Serum parathyroid hormone (PTH) is a recognized marker of bone remodeling in patients with renal osteodystrophy. However, identification of N-terminal truncated PTH fragments and a new form of PTH that interfere with second-generation PTH assays may be responsible for the great variability of PTH values and the difficulties of implementing the recommendations of the National Kidney Foundation/Kidney Disease Outcomes Quality Initiative.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/sj.ki.5001658 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!